Global Licensing Agreement

Alvotech has closed a licensing and settlement agreement with Regeneron and Bayer that clears all patent disputes worldwide over its biosimilar to Eylea. The deal gives Alvotech worldwide rights to manufacture and supply the product to global commercial partners—except for the United States, where a separate agreement had already been announced. Under the terms, partners can market and sell the biosimilar in the United Kingdom, Canada, Japan, and across the European Economic Area from 1 January 2026 until 1 November 2026. The settlement expands Alvotech’s global reach, enabling it to deliver an affordable alternative to a key anti‑VEGF therapy and broadening access for patients internationally. CEO Robert Wessman noted that the commercial partners are well‑positioned for a successful launch and that Alvotech will continue supporting them to enhance global healthcare sustainability. The agreement marks a major milestone, reinforcing Alvotech’s foothold in the biosimilar market and strengthening its strategic positioning in key regions.